Compare Microsoft (MSFT) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microsoft vs Zimmer Biomet Holdings Inc — how do they compare? Microsoft trades at $534.73 (market cap $3.88T), while Zimmer Biomet Holdings Inc trades at $88.84 (market cap $16.95B). The key difference: Microsoft is far larger — about 228.9× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (1.08%). Which is the better fit depends on your goals — on Pluang, investors hold Microsoft for 142 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| MSFT | ZBH | |
|---|---|---|
Market Cap | $3.88T | $16.95B |
Volume | 19,593,392 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $542.07 | $103.98 |
52-Week Low | $352.83 | $79.58 |
Typical Hold Time | 142 Days | 89 Days |
Enterprise Value | $3.86T | $24.02B |
Dividend Yield | 0.75% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microsoft (MSFT) trades at $534.75, up 0.94% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $4.74 surpassing the $4.24 expectation. Revenue grew to $281.72 billion in 2025, and net income reached $101.83 billion, reflecting a robust 40.31% net margin. Analysts maintain a strong buy consensus with an average price target of $571.76, indicating potential upside from current levels.
The outlook for Microsoft remains positive, driven by AI leadership, Azure cloud growth, and solid cash flow generation. Key opportunities include expanding AI services and cloud market share, while risks involve high capital expenditures, competitive pressures, and macroeconomic volatility. The stock's valuation multiples, such as a P/E of 29.11, are elevated but supported by earnings growth and market position.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
